Piermont Capital Management’s Quest Diagnostics DGX Stock Holding History

Piermont Capital Management’s Portfolio DGX Stock Details DGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-5,380	Closed	-$591K	–	134
2018 Q2	$591K	Hold	5,380	–	–	0.18%	138
2018 Q1	$540K	Buy	5,380 +620	+13%	+$63.5K	0.18%	151
2017 Q4	$469K	Hold	4,760	–	–	0.15%	171
2017 Q3	$446K	Sell	4,760 -3,460	-42%	-$367K	0.15%	180
2017 Q2	$914K	Hold	8,220	–	–	0.26%	152
2017 Q1	$807K	Hold	8,220	–	–	0.19%	184
2016 Q4	$755K	Hold	8,220	–	–	0.17%	187
2016 Q3	$696K	Hold	8,220	–	–	0.16%	196
2016 Q2	$669K	Buy	+8,220	New	+$626K	0.17%	205

Other funds holding DGX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

FMI

Fiduciary Management Inc Milwaukee, Wisconsin $8.06B AUM 6.78% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

MWNA

Marshall Wace North America New York $23.5B AUM 46.46% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Bessemer Group Woodbridge, New Jersey $63.6B AUM 28.76% 1-Year Est. Return

Piermont Capital Management's DGX Position: Q3 2018 in Review

Piermont Capital Management sold out of Quest Diagnostics (DGX) in Q3 2018, closing a stake of 5,380 shares — an estimated $591K sold.

Piermont Capital Management first reported a position in DGX in Q2 2016 and held it in 9 quarters. The position peaked at $914K in Q2 2017. 673 funds tracked by Wall St. Rank hold DGX as of Q3 2018.

Piermont Capital Management reported no remaining Quest Diagnostics position as of Q3 2018 after selling out during the quarter.
Piermont Capital Management sold 5,380 Quest Diagnostics shares in Q3 2018, an estimated $591K.
Piermont Capital Management first reported a position in Quest Diagnostics in Q2 2016 and held it in 9 quarters.
Piermont Capital Management's Quest Diagnostics position peaked at $914K in Q2 2017.
673 funds tracked by Wall St. Rank held Quest Diagnostics as of Q3 2018.

Based on Piermont Capital Management's 13F filing for Q3 2018, filed 6 Nov 2018.